CCL20、CCR6及IL-17A在寻常型银屑病患者血清中的表达及意义

Expressions of CCL20,CCR6 and IL-17A in Serum of Patients with Psoriasis Vulgaris

目的观察趋化因子CCL20及其受体CCR6、白细胞介素(IL)-17A在银屑病患者血清中的变化,并探讨其在银屑病发病中的作用。方法采用酶联免疫吸附法测定26例斑块型、7例点滴型银屑病患者及8名健康人血清中CCL20、CCR6及IL-17A的浓度,并对银屑病皮损面积和严重程度指数(PASI)评分、病程进行相关性分析。结果斑块型银屑病患者血清CCL20、CCR6及IL-17A浓度(748.74±268.72,10.20±3.75,39.22±13.21)均显著高于健康对照组(578.45±204.93,6.79±4.61,25.54±13.04)(P分别<0.05,<0.01,<0.01)。点滴型银屑病与对照组差异无统计学意义。CCL20、CCR6与PASI评分呈正相关(r=0.416,r=0.350)(P<0.05)。CCL20、CCR6及IL-17A三者之间均存在显著正相关(r=0.852,r=0.801,r=0.825)(P<0.001),与病程无明显相关性。结论 CCL20、CCR6及IL-17A参与斑块型银屑病的病理过程。

Objective In order to investigate the expressions of CCL20, CCR6 and IL-17A in serum of patients with psoriasis vulgaris, as well as their clinical implications. Methods Serum concentrations of CCL20, CCR6 and IL-17A were detected by ELISA in 26 patients with plaque psoriasis, 7 guttate psoriasis patients and 8 healthy people. Correlations of CCL20, CCR6 and IL-17A with PASI scores and courses of disease were analyzed. Results The concentrations of CCL20, CCR6 and IL- 17A in patients with plaque psoriasis （748.74±268.72,10.20±3.75,39.22±13.21） were significantly higher than those in normal controls （578.45±204.93,6.79±4.61,25.54±13.04） （P〈0.05, 〈0.01, 〈0.01 respectively）. There was no difference between guttate psoriasis patients and normal controls. The concentrations of CCL20 and CCR6 were positively correlated with PASI （r=0.416, r=0.350） （all P〈0.05）. CCL20, CCR6 and IL-17A were significantly positively correlated with each other （r= 0.852, r=0.801, r=0.825） （all P〈0.001 ）, but had no relation with the course of disease （all P〉0.05）. Conclusion CCL20, CCR6 and IL-17A might be involved in the pathogenesis of plaque psoriasis.